TY - JOUR T1 - A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer JF - Cancer Biology & Medicine JO - Cancer Biol Med SP - 136 LP - 139 DO - 10.20892/j.issn.2095-3941.2021.0520 VL - 19 IS - 2 AU - Yuchen Guo AU - Yangyang Zhou AU - Wenxin Qin Y1 - 2022/02/01 UR - http://www.cancerbiomed.org/content/19/2/136.abstract N2 - ER -